Original ArticlesBILATERAL SIMULTANEOUS ENDOGENOUS ASPERGILLUS ENDOPHTHALMITIS IN AN IMMUNOCOMPETENT PATIENTSachdev, Nishant MD*; Gupta, Pawan MD*; Singh, Ramandeep MD*; Chakrabarti, Arunaloke MD†; Gupta, Vishali MD*; Gupta, Amod MD*Author Information From the Departments of *Ophthalmology and †Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Reprint requests: Amod Gupta, MD, Department of Ophthalmology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India; e-mail: [email protected] Retinal Cases & Brief Reports: Winter 2010 - Volume 4 - Issue 1 - p 14-17 doi: 10.1097/ICB.0b013e318196b26c Buy Metrics AbstractIn Brief Purpose: To report a case of bilateral endogenous Aspergillus endophthalmitis in an immunocompetent patient. Methods: We report a young immunocompetent 26-year-old Indian woman who presented with bilateral simultaneous endogenous endophthalmitis and was managed with pars plana vitreous surgery in both the eyes. Results: Smear examination of the vitrectomy specimen from the left eye identified septate hyphae with acute-angle branching, which on culture showed growth of Aspergillus fumigatus. A detailed systemic evaluation failed to reveal any systemic focus or predisposing factor for fungal infection. The patient had received an intravenous dextrose infusion 2 weeks before this episode while being treated at a rural hospital for malarial infection. During follow-up, she developed bilateral rhegmatogenous retinal detachment requiring revised pars plana vitreous surgery with silicon oil tamponade. Conclusion: An immunocompetent patient can present with bilateral simultaneous endogenous Aspergillus endophthalmitis after receiving an intravenous infusion of presumably contaminated dextrose solution. An immunocompetent patient can present with bilateral simultaneous endogenous Aspergillus endophthalmitis after receiving intravenous infusion of presumably contaminated dextrose solution. © 2010 Ophthalmic Communications Society, Inc.